BTK and primary central nervous system lymphoma: However, brain exposure to ibrutinib and two other approved BTK inhibitors is low, and the penetration rates (%, Cmax,brain/Cmax,plasma) are all below 10%, which may hinder their efficacy in treating CNS lymphoma.17